在阿尔茨海默病中增强阿普坦选择:整合结构预测和分子动力学模拟
Benedikt Jakob Lohnes1,2,3, Aaron John Goff1,4, Udo Frank Hartwig2,3
1Department of Biosciences, Manipal University Jaipur, Village-Dehmi Kalan, Ajmer Expressway, Jaipur, 303007, Rajasthan, India.
Scientific reports
|July 23, 2025
概括
计算策略简化了阿尔茨海默病治疗方法的体选择. 由于高可预测性和有利的结合相互作用,DNA吸收体显示出有前途,为向治疗铺平了道路.
科学领域:
- 生物化学 生物化学
- 计算生物学 计算生物学
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病是全球痴呆的主要原因.
- 阿普塔默对阿尔茨海默病点具有很高的亲和力,但治疗开发需要进一步比较它们的特性.
- 简化阿帕特默选择对于开发有效的疾病修饰治疗至关重要.
研究的目的:
- 为了比较阿尔茨海默病的aptamers的生物化学特性和向相互作用.
- 为了评估计算策略在预测aptamer有效性的实用性.
- 为了识别参与阿普坦-标结合的关键氨基酸.
主要方法:
- 使用生物信息学预测2D和3D体结构.
- 分子动力学,分子对接,和MM/PBSA模拟的aptamer-target复合体.
- 结合亲和力和相互作用的分析.
主要成果:
- 在实验亲和力和预测的结合自由能量之间观察到强烈的相关性.
- DNA 体表现出高可预测性,表现优于RNA 体.
- 酸体表现出较低的对接得分.
- 疏水性和基本氨基酸 (氨酸,氨酸,氨酸,氨酸) 是阿普坦酶结合的关键.
结论:
- 计算策略有效地简化了阿尔茨海默病的胃细胞选择.
- DNA 体是治疗开发的有希望的候选者.
- 疏水口袋和离子相互作用介导着阿普他默结合,使得阿尔茨海默病的向治疗成为可能.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.亚普特美尔 (Aptamer) 是一种药物.良好的健康和福祉在MM/PBSA中,可以选择MM/PBSA.分子对接 分子对接分子动力学分子动力学结构预测结构预测更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
671
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.9K
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262